ORIGINAL RESEARCH article
Front. Chem.
Sec. Medicinal and Pharmaceutical Chemistry
Volume 13 - 2025 | doi: 10.3389/fchem.2025.1638489
This article is part of the Research TopicRecent Advances in Synthetic Organic Chemistry at the Biomedical Interface: Honoring Professor Iwao Ojima on the Occasion of his 80th BirthdayView all 21 articles
Design, synthesis, antiproliferative assessments, and computational studies of new quinolin-2(1H)-ones as dual EGFR/HER-2 inhibitors
Provisionally accepted- 1Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
- 2Deraya University, Minya, Egypt
- 3Helsinki University Press, Helsinki, Finland
- 4Karlsruher Institut fur Technologie, Karlsruhe, Germany
- 5Assiut University, Assiut, Egypt
- 6Assiut University, Asyut, Egypt
- 7Minia University, Minya, Egypt
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
A novel series of quinolin-2(1H)-one derivative was rationally designed, synthesized, and characterized as potential dual inhibitors of EGFR and HER-2. Structural elucidation was achieved through IR, NMR, mass spectrometry, elemental analysis, and single-crystal X-ray crystallography. The synthesized compounds were screened for antiproliferative activity against four human cancer cell lines. Compound 5a exhibited the most potent antiproliferative profile, particularly against MCF-7 breast cancer cells (IC₅₀ = 34 nM), outperforming erlotinib (IC₅₀ = 40 nM). Kinase inhibition assays further confirmed dual activity of 5a, with IC₅₀ values of 87 nM and 33 nM against EGFR and HER-2, respectively. Compound 5a induced apoptosis via activation of caspase-3, -8, and -9, along with upregulation of Bax, downregulation of Bcl-2, and increased cytochrome c release. Flow cytometry analysis demonstrated that 5a caused significant G0/G1 phase arrest in MCF-7 cells, indicating a cytostatic mechanism of action. Computational studies provided structural validation of the observed biological activities. Molecular docking studies showed a strong binding affinity 5a within the ATP-binding pockets of EGFR and HER-2, supported by key hydrogen bonding and hydrophobic interactions. These findings were further corroborated by 100 ns molecular dynamics simulations, which confirmed the structural stability and compactness of the 5a-HER-2 complex, as evidenced by low RMSD, consistent RMSF, and favorable radius of gyration and potential energy profiles. Additionally, ADME predictions revealed that 5a possesses favorable physicochemical and pharmacokinetic properties. Density Functional Theory (DFT) calculations provided insights into the electronic structure of 5a, highlighting favorable HOMO–LUMO distribution and electrostatic potential surfaces that support its dual-binding behavior.
Keywords: Quinoline, kinases, x-ray, DFT, anticancer, EGFR, HER-2
Received: 30 May 2025; Accepted: 01 Sep 2025.
Copyright: © 2025 Al-Wahaibi, Abou-Zied, Nieger, Bräse, Youssif and Mohamed. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Stefan Bräse, Karlsruher Institut fur Technologie, Karlsruhe, Germany
Bahaa G. M. Youssif, Assiut University, Assiut, Egypt
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.